A Study to Test How Well Overweight Men Tolerate Different Doses of BI 3006337
Status:
Recruiting
Trial end date:
2022-06-21
Target enrollment:
Participant gender:
Summary
The main objectives of this trial are to investigate safety, tolerability and
pharmacokinetics of BI 3006337 in overweight, healthy male subjects following subcutaneous
administration of single-rising doses.